QA: Longeveron Inc in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001721484_2023_Longeveron_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}
warning Missing logo subcommand.report {}
info NetIncome node detected by revenue/expenses heuristic input.sec.calculation_linkbase.edgar_model_mapping {'net_inc_node': 'OperatingIncomeLoss'}

Graph

Absolute values for 0001721484, Longeveron Inc

  xvar xval
0 AssetsCurrent 20,280,000
1 IntangibleAssetsNetIncludingGoodwill 2,409,000
2 PropertyPlantAndEquipmentNet 2,949,000
3 remainder_Assets 1,775,000
4 LiabilitiesCurrent 4,869,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 2,041,000
7 CostOfGoodsAndServicesSold 725,000
8 SellingGeneralAndAdministrativeExpense 8,119,000
9 ResearchAndDevelopmentExpense 9,370,000
10 remainder_Expenses 1,051,000
11 remainder_Revenues 1,222,000
12 remainder_NetIncome 0
13 remainder_ComprehensiveNetIncome -435,000
  yvar yval
0 Assets 27,413,000
1 Liabilities 6,910,000
2 Expenses 19,265,000
3 Revenues 1,222,000
4 StockholdersEquity 20,503,000
5 NetIncome -18,043,000
6 ComprehensiveNetIncome -18,260,500
7 BaseVar 27,622,500
8 EconomicCapitalRatiobeforeLimitedLiability 1.54
9 EconomicCapitalRatio 2.71

Edgar->Model Mapping

Feature Distribution